Compass Therapeutics (CMPX) News Today → With revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radar (From Stocks News) (Ad) Free CMPX Stock Alerts $1.54 -0.07 (-4.35%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 4:50 PM | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Compass Therapeutics (CMPX)May 14 at 4:50 PM | markets.businessinsider.comBuy Rating Affirmed for Compass Therapeutics on Strong Financials and Promising Clinical TrialsMay 14 at 12:31 PM | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Compass Therapeutics in a research report on Tuesday.May 14 at 8:00 AM | globenewswire.comCompass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 13 at 3:48 PM | investorplace.comCMPX Stock Earnings: Compass Therapeutics Beats EPS for Q1 2024May 13 at 8:00 AM | globenewswire.comCompass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate UpdateApril 25, 2024 | finance.yahoo.comCompass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously TreatedApril 17, 2024 | benzinga.comCompass Therapeutics Stock (NASDAQ:CMPX), Analyst Ratings, Price Targets, PredictionsApril 16, 2024 | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Compass Therapeutics in a research note on Tuesday.April 14, 2024 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Sees Large Decline in Short InterestCompass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the target of a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 1,620,000 shares, a drop of 13.8% from the March 15th total of 1,880,000 shares. Approximately 2.0% of the company's stock are short sold. Based on an average daily volume of 485,500 shares, the days-to-cover ratio is currently 3.3 days.April 12, 2024 | globenewswire.comCompass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual ConferenceApril 11, 2024 | investing.comCompass Therapeutics reports potential in tumor treatmentApril 10, 2024 | finance.yahoo.comCompass Therapeutics to Participate in the Stifel Targeted Oncology DaysApril 10, 2024 | globenewswire.comCompass Therapeutics to Participate in the Stifel Targeted Oncology DaysApril 9, 2024 | globenewswire.comCompass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual MeetingMarch 25, 2024 | markets.businessinsider.comCompass Therapeutics: A Strong Buy on Promising Clinical Pipeline and Strategic MilestonesMarch 24, 2024 | investorplace.com3 Penny Stocks With the Power to 10X Your $1K InvestmentMarch 22, 2024 | marketbeat.comCompass Therapeutics' (CMPX) "Outperform" Rating Reaffirmed at WedbushWedbush reaffirmed an "outperform" rating and issued a $8.00 target price on shares of Compass Therapeutics in a research note on Friday.March 22, 2024 | markets.businessinsider.comCompass Therapeutics’ Strategic Advancements and Strong Financials Prompt Buy RatingMarch 21, 2024 | marketbeat.comCompass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Compass Therapeutics in a research note on Thursday.March 21, 2024 | globenewswire.comCompass Therapeutics Reports 2023 Financial Results and Provides Corporate UpdateMarch 18, 2024 | marketbeat.comShort Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Declines By 6.6%Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) saw a significant decrease in short interest in February. As of February 29th, there was short interest totalling 1,840,000 shares, a decrease of 6.6% from the February 14th total of 1,970,000 shares. Based on an average daily volume of 527,500 shares, the days-to-cover ratio is presently 3.5 days. Approximately 2.4% of the company's shares are short sold.March 12, 2024 | finance.yahoo.comWith 52% ownership of the shares, Compass Therapeutics, Inc. (NASDAQ:CMPX) is heavily dominated by institutional ownersMarch 8, 2024 | marketbeat.comFmr LLC Decreases Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)Fmr LLC lowered its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 17.7% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,553,093 shares of the company's stock after selling 982,413 shares duFebruary 29, 2024 | globenewswire.comCompass Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceFebruary 28, 2024 | finance.yahoo.comCompass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical TrialFebruary 25, 2024 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Monashee Investment Management LLCMonashee Investment Management LLC lowered its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 37.7% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,226,142 shares of the company's stock after selling 743,15February 8, 2024 | msn.comCompass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should KnowFebruary 8, 2024 | marketbeat.comLeerink Partnrs Comments on Compass Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:CMPX)Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2024 earnings per share estimates for shares of Compass Therapeutics in a research note issued on Monday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will pFebruary 2, 2024 | morningstar.comCompass Therapeutics Inc Ordinary SharesJanuary 31, 2024 | finance.yahoo.comWe're Not Very Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn RateJanuary 15, 2024 | marketbeat.comShort Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Grows By 8.1%Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,270,000 shares, an increase of 8.1% from the December 15th total of 2,100,000 shares. Based on an average daily volume of 514,700 shares, the days-to-cover ratio is presently 4.4 days. Currently, 2.8% of the company's stock are short sold.January 5, 2024 | finance.yahoo.comCompass Therapeutics Provides Corporate UpdateDecember 31, 2023 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest UpdateCompass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 2,100,000 shares, a decline of 21.3% from the November 30th total of 2,670,000 shares. Currently, 2.6% of the shares of the stock are sold short. Based on an average trading volume of 356,400 shares, the short-interest ratio is presently 5.9 days.December 20, 2023 | finance.yahoo.comCompass Therapeutics Insider Ups Holding During YearNovember 17, 2023 | finance.yahoo.comCompass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 17, 2023 | finance.yahoo.comCompass Therapeutics Inc (CMPX) Reports Q3 2023 Financial Results and Corporate DevelopmentsNovember 14, 2023 | msn.comCompass Therapeutics, Inc. (CMPX) Loses -28.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerNovember 3, 2023 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on COMPASS Pathways (CMPS)September 27, 2023 | theglobeandmail.comInstrument Name Compass Therapeutics Inc Instrument Symbol (CMPX-Q)August 24, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn SituationAugust 3, 2023 | msn.comHC Wainwright & Co. Reiterates Compass Therapeutics (CMPX) Buy RecommendationAugust 3, 2023 | msn.comCompass Therapeutics GAAP EPS of -$0.09August 3, 2023 | finance.yahoo.comCompass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJune 22, 2023 | msn.comCompass Therapeutics added to Russell indexesJune 22, 2023 | finance.yahoo.comCompass Therapeutics to be Added to the Russell 2000® and Russell 3000® IndexesJune 22, 2023 | finance.yahoo.comCompass Therapeutics to be Added to the Russell 2000® and Russell 3000® IndexesJune 4, 2023 | marketbeat.comCitigroup Inc. Boosts Position in Compass Therapeutics, Inc. (NASDAQ:CMPX)Citigroup Inc. boosted its holdings in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Rating) by 2,686.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 126,315 shares of the company's stock after buying an additionalJune 1, 2023 | finance.yahoo.comCompass Therapeutics to Participate in Upcoming Investor EventsMay 31, 2023 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of "Buy" from BrokeragesShares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Rating) have been given an average rating of "Buy" by the seven brokerages that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month price target Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Wall Street legend who predicted 2021 tech crash issues new warning (Ad)People around the world follow 50-year Wall Street veteran Marc Chaikin for his surprisingly accurate stock predictions. And he just issued an urgent WARNING for some of the most popular stocks in U.S. history. Watch his stock warning right here, 100% free of charge CMPX Media Mentions By Week CMPX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMPX News Sentiment▼0.840.55▲Average Medical News Sentiment CMPX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMPX Articles This Week▼91▲CMPX Articles Average Week Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ZURA News ABOS News PCB News AGEN News IPHA News OPT News INMB News CHRS News IPSC News KOD News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMPX) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAmazon's betting big on this unknown AI companyManward PressWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingProtect Your Bank Account Before It’s Too LateWeiss RatingsGold Set to EXPLODE!Gold Safe Exchange"The Biggest Drug Ever" Is ComingBehind the MarketsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
